Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs 8x8 Inc (EGHT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs 8x8 Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287 (market cap $39.89B), while 8x8 Inc trades at $2.2 (market cap $290.65M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 137.2× 8x8 Inc's market cap, and 8x8 Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | EGHT | |
|---|---|---|
Market Cap | $39.89B | $290.65M |
Sector | Health | Technology |
52-Week High | $491.22 | $2.76 |
52-Week Low | $278.09 | $1.59 |
Enterprise Value | $38.15B | $568.33M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
EGHT trades at $2.05, down 0.49% today, with a bullish technical signal from moving averages. The company shows strong revenue growth with Q4 2026 earnings beating estimates at $0.11 per share versus $0.07 expected. Recent positive news includes AI product launches and industry recognition, though profitability remains weak with a net margin of just 0.22% and negative retained earnings of -$887.72 million.
Outlook is mixed with analyst consensus leaning neutral (39% buy, 43% hold). Key opportunities include AI-driven product expansion and consistent earnings beats, while risks involve high debt levels, thin margins, and competitive pressures in the CPaaS space. The stock's high P/E ratio of 205 suggests growth expectations are priced in.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →
